header
February 12, 2021

In This Issue
MMA Weekly State Vaccination Plan Update
MMA Leadership & Staff Share Condolences on Passing of George Smith
Maine PMP to Stay with Appriss System
Next Maine CDC COVID-19 Update for Clinicians with Stephen Sears, MD scheduled for Feb 25
Federal Government Finalizes Purchase of 200M COVID-19 Vaccines Doses
US CDC: Fully Vaccinated Meeting Criteria No Longer Required to Quarantine After Exposure
AMA President: Physicians & Medical Societies Can Play Vital Role Advocating for Strong Public Health
NEJM: The FDA’s Experience with Covid-19 Antibody Tests
NEJM: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Monoclonal Antibody Authorization from the FDA (Updated 02/09/21) & MaineCare Reimbursement
Guidance for Industry: Investigational COVID-19 Convalescent Plasma (Updated 02/11/20)
Maine Legislative Leadership COVID-19 Bill Set for Public Hearing Tuesday
Next MMA Legislative Call Will Be Wednesday, February 17th
Daniel Hanley Center for Health Leadership’s Renowned Physician Executive Leadership Institute – The Advanced Course Enrollment is OPEN
PPE Available Through the MMA & ActionPPE
A Message from Maine Responds: Volunteer Opportunity
MAINE LEGISLATURE
Maine Legislature Week 5 Update
Upcoming Public Hearings & Work Sessions; New Bills Introduced
UPCOMING EVENTS
Upcoming Specialty Society Meetings
Maine CDC Physicians To Host Regular Clinician COVID Vaccine Info Sessions
Suicide Prevention and Management in Healthcare Practice Settings: A Comprehensive Evidence-Based Approach
MOA VIRTUAL Midwinter Symposium - February 12th-14th
Maine CDC Annual Prevention Professionals Conference - March 2nd-3rd
AAP EQIPP Course: Immunizations - Strategies for Success (for RURAL Health Providers)
HEALTHCARE EMPLOYMENT OPPORTUNITIES
Physician (BC/BE in Family Medicine)
Nursing Director
Medical Director - Bucksport Regional Health Center
Rangeley Family Medicine seeks Physician

 
Search Back Issues



 

 

 


Follow Us:
Monoclonal Antibody Authorization from the FDA (Updated 02/09/21) & MaineCare Reimbursement

FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19  (Guidance Document 02/11/21) 

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) this week for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19. The authorized use includes treatment for those who are 65 years of age or older or who have certain chronic medical conditions. 

Maine Care Claims for Monoclonal Antibody Product and Infusion Codes, CR 99700 (Updated 02/10/21) 

Providers of MaineCare Benefits Manual, Section 90 and Section 45 services may submit claims for the delivery of Monoclonal Antibody COVID-19 Infusion treatments when they are delivered on or after the respective effective dates for each product and in accordance with the for each product. 

Please review the Fact Sheets for Health Care Providers of EUA of Bamlanivimab and Casirivimab & Imdevimab for the limitations of authorized use. 

More information on various codes and their rates can be found here.

 

    

< Previous Article | Next Article >

[ return to top ]

To ensure delivery of Maine Medicine Weekly Update,
please add 'info@mainemed.com' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm


Unsubscribe here

For more information or to contact us directly, please visit www.mainemed.com | ©